Bridging Kidney Organoid Innovation and Regenerative Medicine: Current Advances and Future Directions
Cell Proliferation · 2026-07 · 59 (7)
DOI: 10.1111/cpr.70228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Proliferation, online erschienen am 15.05.2026. Verfasst von Bohong Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital, Henan University, Kaifeng, China. Hauptthemen laut MEDLINE: Regenerative Medicine, Organoids, Kidney. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Chronic kidney disease (CKD) has emerged as a critical public health challenge worldwide, and organ donor shortages underscore the urgent need for alternative therapeutic strategies. Advances in stem cell technologies have enabled the generation of kidney organoids, providing innovative platforms to model renal development, investigate disease mechanisms, support drug discovery, and explore applications in regenerative medicine. Yet, limitations such as immature tissue architecture, insufficient vascularisation, and unaddressed safety concerns still hinder their translation into regenerative medicine. In this review, we summarise the fundamentals of kidney development, current differentiation approaches, and the signalling and epigenetic mechanisms underlying organoid lineage specification. We further highlight the roles of bioengineering innovations and single‐cell transcriptomics in establishing evaluation frameworks and enhancing structural complexity. We finally emphasise that existing optimisation frameworks, primarily focused on improving differentiation efficiency and enforcing relatively restricted lineage specification, may prove inadequate for bridging the gap to clinical translation. Instead, the most promising paradigm shift involves the convergence of bioengineering modulation and high‐resolution functional assessment to facilitate the synchronised advancement of organoid complexity and physiological utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital, Henan University, Kaifeng, China.
- Laboratory of Receptor Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Henan University, Kaifeng, China.
- Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Guangzhou, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- China Postdoctoral Science Foundation
- Science and Technology Department of Henan Province
- Students' Innovation and Entrepreneurship Training Program of Henan University
Zitieren
APA
Guo, B., Zhang, J., Fang, X., Liu, Y., Deng, Y., Xue, Y., Wang, Z., Dong, X., Jia, M., & Li, X. (2026). Bridging Kidney Organoid Innovation and Regenerative Medicine: Current Advances and Future Directions. Cell Proliferation, 59(7). https://doi.org/10.1111/cpr.70228
Vancouver
Guo B, Zhang J, Fang X, Liu Y, Deng Y, Xue Y, et al. Bridging Kidney Organoid Innovation and Regenerative Medicine: Current Advances and Future Directions. Cell Proliferation. 2026;59(7). doi:10.1111/cpr.70228
BibTeX
@article{Guo2026,
author = {Guo, Bohong and Zhang, Jingyuan and Fang, Xuening and Liu, Yangyang and Deng, Yueyang and Xue, Yuxin and Wang, Zhengxi and Dong, Xiaotao and Jia, Mengqi and Li, Xiaodong},
title = {Bridging Kidney Organoid Innovation and Regenerative Medicine: Current Advances and Future Directions},
journal = {Cell Proliferation},
year = {2026},
volume = {59},
number = {7},
doi = {10.1111/cpr.70228}
}
EUVIMED